LakePharma
Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help partners turn ideas into impact. With over 30 years of experience, a network of 20+ global sites, and 3,100+ employees, Curia collaborates closely with pharmaceutical and biotechnology companies to accelerate the delivery of life-changing therapies. The company provides solutions in small molecules, generic APIs, and biologics, backed by deep scientific expertise and advanced technologies, from discovery through commercialization.
Industries
Nr. of Employees
medium (51-250)
LakePharma
24 Corporate Circle, Albany, NY 12203, USA
Products
Phage and Yeast Display
Platforms for in vitro discovery and engineering of antibody candidates, including access to diverse libraries and lead antibody characterizations.
Antibody Discovery & Engineering Services
Comprehensive services for the identification, optimization, and characterization of new antibody leads.
GMP Manufacturing of mRNA, Antibodies, Proteins, and Vaccines
ISO 13485:2016 certified facilities for GMP manufacturing of biologics, including mRNA, antibodies, proteins, and vaccines.
Viral Vector Platforms
Services for stable cell line development and clone isolation using viral vectors like Baculovirus, AAV, and Lentivirus.
Plasmid DNA Services
Services for gene synthesis, PCR cloning, mutagenesis, custom cloning, plasmid design and construction, scale-up, and DNA sequencing and analysis.
Hybridoma Technologies
Platform for the discovery of therapeutic or diagnostic monoclonal antibodies with a high success rate.
Phage and Yeast Display
Platforms for in vitro discovery and engineering of antibody candidates, including access to diverse libraries and lead antibody characterizations.
Antibody Discovery & Engineering Services
Comprehensive services for the identification, optimization, and characterization of new antibody leads.
GMP Manufacturing of mRNA, Antibodies, Proteins, and Vaccines
ISO 13485:2016 certified facilities for GMP manufacturing of biologics, including mRNA, antibodies, proteins, and vaccines.
Viral Vector Platforms
Services for stable cell line development and clone isolation using viral vectors like Baculovirus, AAV, and Lentivirus.
Plasmid DNA Services
Services for gene synthesis, PCR cloning, mutagenesis, custom cloning, plasmid design and construction, scale-up, and DNA sequencing and analysis.
Hybridoma Technologies
Platform for the discovery of therapeutic or diagnostic monoclonal antibodies with a high success rate.
Services
End‑to‑end discovery support including assay development, high‑throughput screening, in vitro biology, antibody discovery and lead optimization delivered from dedicated discovery sites.
Custom synthesis, chemical process R&D and GMP API manufacture including controlled substances, steroids/hormones and high‑potency APIs.
Mammalian cell-line development, upstream/downstream process development, GMP mammalian and mRNA manufacturing, and formulation to drug‑substance release.
Formulation and process development for sterile injectables plus clinical and commercial aseptic fill‑finish, lyophilization and automated inspection/packaging.
Batch release, stability testing, method development and GLP/GMP validation, solid‑state chemistry and container/closure qualification.
End‑to‑end discovery support including assay development, high‑throughput screening, in vitro biology, antibody discovery and lead optimization delivered from dedicated discovery sites.
Custom synthesis, chemical process R&D and GMP API manufacture including controlled substances, steroids/hormones and high‑potency APIs.
Mammalian cell-line development, upstream/downstream process development, GMP mammalian and mRNA manufacturing, and formulation to drug‑substance release.
Formulation and process development for sterile injectables plus clinical and commercial aseptic fill‑finish, lyophilization and automated inspection/packaging.
Batch release, stability testing, method development and GLP/GMP validation, solid‑state chemistry and container/closure qualification.
Expertise Areas
- Small molecule discovery and development
- API manufacturing and chemical process development
- Biologics discovery, engineering and manufacture
- mRNA and self‑replicating RNA (srRNA) process development
Key Technologies
- Next‑generation sequencing (NGS) for antibody discovery
- Optofluidic single‑cell selection and screening
- High‑throughput Surface Plasmon Resonance (HT‑SPR)
- Flow chemistry and flow photochemistry reactors
News & Updates
Curia received the 2025 CDMO Leadership Award in the Global Biologics category, recognizing its investment in biologics capabilities and support for partners.
Curia announced expansion plans in Glasgow, UK, and updates on Albuquerque, NM, facilities to increase capacity for sterile injectable products.
Curia announced refinancing to support continued growth, including investments in facilities in New York and UK.
Curia India Pvt Ltd ranked in the Nature Index.
Curia announced its commitment to the Science Based Targets initiative (SBTi) Net-Zero Standard.
Curia unveiled a new brand identity at CPHI WW in Milan.
Curia received the 2025 CDMO Leadership Award in the Global Biologics category, recognizing its investment in biologics capabilities and support for partners.
Curia announced expansion plans in Glasgow, UK, and updates on Albuquerque, NM, facilities to increase capacity for sterile injectable products.
Curia announced refinancing to support continued growth, including investments in facilities in New York and UK.
Curia India Pvt Ltd ranked in the Nature Index.
Curia announced its commitment to the Science Based Targets initiative (SBTi) Net-Zero Standard.
Curia unveiled a new brand identity at CPHI WW in Milan.